LMAT Stock Forecast: LeMaitre Vascular, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering LeMaitre Vascular, Inc. hold a median 12-month price target of $91 — +23.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 69 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores LeMaitre Vascular, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (96): The share price has been relatively steady.
Revisions (36): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
LMAT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LMAT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +23.6% from it.
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | Citizens | Maintains | Market Outperform | $127 → $110 |
| 5 Nov 2026 | Wells Fargo | Maintains | Equal-Weight | $94 → $86 |
| 5 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $104 → $94 |
| 3 June 2026 | Barrington Research | Maintains | Outperform | $120 |
| 6 May 2026 | Barrington Research | Maintains | Outperform | — |
| 6 May 2026 | Citizens | Maintains | Market Outperform | — |
| 6 May 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 26 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 26 Feb 2026 | Citizens | Maintains | Market Outperform | — |
| 26 Feb 2026 | Roth Capital | Reiterates | Buy | — |
| 26 Feb 2026 | Wells Fargo | Maintains | Equal-Weight | — |
| 20 Feb 2026 | Barrington Research | Maintains | Outperform | — |
| 7 Nov 2025 | Wells Fargo | Maintains | Equal-Weight | — |
| 5 Nov 2025 | Roth Capital | Reinstates | Buy | $108 |
| 15 Oct 2025 | Barrington Research | Maintains | Outperform | — |
| 23 Sept 2025 | Barrington Research | Maintains | Outperform | — |
| 6 Aug 2025 | Barrington Research | Upgrade | Outperform | — |
| 6 Aug 2025 | Cantor Fitzgerald | Maintains | Neutral | — |
| 22 July 2025 | Barrington Research | Reiterates | Market Perform | — |
| 28 Feb 2025 | Barrington Research | Downgrade | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LMAT.
This page is one stock. Monday covers all of them.
LMAT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
LMAT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, LeMaitre Vascular, Inc. returned −11.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
LMAT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 27.9×
- Price / sales
- 6.4×
- Price / book
- 4.0×
- EV / EBITDA
- 19.6×
Cheaper than 31% of US stocks
Cheaper than 17% of US stocks
Cheaper than 23% of US stocks
Cheaper than 21% of US stocks
- Revenue growth (YoY)
- 11.3%
- Earnings growth (YoY)
- −13.5%
- Gross margin
- 72.1%
- Operating margin
- 24.7%
- Net margin
- 23.5%
Higher than 57% of US stocks
Higher than 24% of US stocks
Higher than 84% of US stocks
Higher than 84% of US stocks
Higher than 84% of US stocks
- Return on equity
- 15.6%
- Return on assets
- 6.6%
- Dividend yield
- 1.3%
Higher than 75% of US stocks
Higher than 83% of US stocks
Higher than 28% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
LeMaitre Vascular, Inc. has a market value of $1.7B and an enterprise value of $1.5B.
Revenue in the twelve months to 30 June 2026: $262.4M. The latest quarter grew 9.6% year on year.
Net income over the same four quarters: $65.7M, a 25.0% net margin.
Diluted earnings per share, trailing twelve months: $2.85.
Free cash flow in the twelve months to 30 June 2026: $73.8M.
LeMaitre Vascular, Inc. spent $20.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 27.9×; forward P/E: 24.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.33%, paying out 35% of earnings.
LeMaitre Vascular, Inc. employs 646 people — $406K of revenue per employee.
Data provided by Twelve Data
LMAT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at LMAT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own LeMaitre Vascular, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about LMAT
What is the LMAT stock price forecast for 2026-2027?
The 8 Wall Street analysts covering LeMaitre Vascular, Inc. have a median 12-month price target of $91, with estimates ranging from $81 to $132. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is LMAT stock a buy right now?
Of the 8 analysts covering LeMaitre Vascular, Inc., 4 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeMaitre Vascular, Inc. 69 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank LMAT?
As at 21 Nov 2026, LeMaitre Vascular, Inc. ranks 69 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).
Will LMAT stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +23.6% from the last close, and Ticker Nerd's factor model ranks LeMaitre Vascular, Inc. 69 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the LMAT stock forecast for 2030?
No analyst covering LeMaitre Vascular, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LMAT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $81 to $132 over the next 12 months.
How has LMAT stock performed over the past year?
LeMaitre Vascular, Inc. returned -11.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does LeMaitre Vascular, Inc. do?
LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease. The company develops, manufactures, and markets a specialized portfolio that includes biologic patches, vascular grafts, catheters, carotid shunts, valvulotomes, radiopaque marking tape, and other disposable and implantable tools used to repair blood vessels and support bypass, access, and clot-removal procedures.
About LeMaitre Vascular, Inc.
LeMaitre Vascular Inc. is a medical device company focused on products and services used in vascular surgery and the treatment of peripheral vascular disease. The company develops, manufactures, and markets a specialized portfolio that includes biologic patches, vascular grafts, catheters, carotid shunts, valvulotomes, radiopaque marking tape, and other disposable and implantable tools used to repair blood vessels and support bypass, access, and clot-removal procedures. LeMaitre Vascular also provides human tissue cryopreservation services for implantation, adding a complementary service component to its device business. Its offerings are used by vascular surgeons and related specialists in hospitals and surgical settings, giving the company a focused role in a niche segment of the broader medical technology market.
CEO Mr. George W. LeMaitre · 646 employees · United States · https://www.lemaitre.com